Harbin Pharmaceutical Soars 10.13%, Hits Intraday High of CNY 3.37

Harbin Pharmaceutical Group Co., Ltd. has experienced a significant uptick in its stock performance, gaining 10.13% on July 10, 2026. The stock reached an intraday high of CNY 3.37, marking a notable achievement amid a challenging market environment. In comparison, the China Shanghai Composite index declined by 1.0% on the same day, highlighting Harbin's relative strength. Over the past week, Harbin Pharmaceutical has shown a 7.32% increase, while its one-month performance stands at 8.36%. However, the company has faced difficulties over the longer term, with a one-year decline of 12.24% and a year-to-date performance of -2.32%. Despite these challenges, the stock has outperformed the China Shanghai Composite over the last five years, with an 18.66% increase compared to the index's 13.4%. Key financial metrics indicate a mid-cap company with a market capitalization of CNY 7,830 million. The price-to-earnings ratio is currently at 23.00, and the return on equity is reported at 5.82%. As the company navigates its financial landscape, today's performance reflects a moment of resilience in a fluctuating market.